ProtonDx joins PACE-AMR to help tackle UTIs

High-impact antimicrobial resistance innovations programme chooses Dragonfly to be adapted as a new, rapid test for the effective management of urinary tract infections (UTIs).

London, UK, 24 November 2025: We are immensely proud to be selected for the PACE-AMR programme, a vital initiative dedicated to accelerating high-impact antimicrobial resistance (AMR) innovations.

This partnership enables us to adapt Dragonfly™, our existing portable diagnostics platform, to develop a new, rapid test for the effective management of urinary tract infections (UTIs).

Having already been validated for respiratory viruses, malaria and MPXV, the sample-to-result workflow is ready to be adapted for urine-based UTI testing to report results at clinically relevant levels within 30 minutes.

Read more about how we are working to improve patient outcomes and antimicrobial stewardship on the PACE-AMR website.